1. Market Research
  2. > Pathology
19 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030

  • $ 2850
  • May 2020
  • 100 pages

Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030 ##.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • Germany

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast to 2030

  • $ 4750
  • May 2020
  • 200 pages

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Drug Chapters Drug chapter segment of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer report encloses the detailed analysis of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer marketed drugs and late stag

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • United States

B-cell Non-Hodgkin’s Lymphoma—Market Insights, Epidemiology, and Market Forecast—2028

  • $ 6250
  • January 2020
  • 287 pages

Burkitt Lymphoma ##. ##. ##.

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • United States

Peripheral T-Cell Lymphoma Epidemiology Forecast to 2030

  • $ 3750
  • July 2020
  • 100 pages

Anaplastic Large Cell Lymphoma (ALCL) ##. ##. ##.

  • Cancer
  • Lymphoma
  • Pathology
  • Germany
  • United States

Cutaneous T- Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2028

  • $ 3250
  • January 2020
  • 189 pages

More than ## out of every ## skin lymphomas diagnosed are CTCLs.

  • Cancer
  • Lymphoma
  • Pathology
  • United States
  • Market Size

Peripheral T-Cell Lymphoma (PTCL)—Market Insights, Epidemiology and Market Forecast–2030

  • $ 6950
  • July 2020
  • 290 pages

Anaplastic Large Cell Lymphoma (ALCL) ##. ##. ##.

  • Lymphoma
  • Therapy
  • United States

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) - Market Insights and Market Forecast-2030

  • $ 6950
  • April 2020
  • 200 pages

And phase II in Relapsed/ Refractory Mantle Cell Lymphoma.

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Therapy
  • United States

Focal Segmental Glomerulosclerosis (FSGS)- Market Insight, Epidemiology and Market Forecast -2030

  • $ 6950
  • April 2020
  • 187 pages

Overview for Current and Future Therapies: ##. ## Future Therapies: ## Market Drivers ## Market Barriers ## Case Studies ##. ## A Case Report of Focal Segmental Glomerulosclerosis (FSGS) in a patient with Mantle Cell Lymphoma (MCL) - Rare presentation ##. ## A Successfully Treated Case of Recurre

  • Lymphoma
  • Therapy
  • United States
  • Market Size

Indolent Lymphoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

  • $ 2000
  • January 2020
  • 60 pages

Indolent Lymphoma ##. ##.

  • Cancer
  • Lymphoma
  • United States
  • World

Anaplastic Lymphoma Kinase (ALK) Inhibitor -Pipeline Insight, 2020

  • $ 1500
  • June 2020
  • 60 pages

Anaplastic Lymphoma Kinase (ALK) Inhibitor ##. ##.

  • Lymphoma
  • Therapy

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Insight, 2019

  • $ 1250
  • February 2020
  • 106 pages

Anaplastic Large Cell Lymphoma (ALCL) - Disease Overview ##.

  • Lymphoma

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) - Market Insights, Epidemiology, and Market Forecast - 2030

  • $ 6950
  • April 2020
  • 141 pages

BPDCN can be referred by different names such as blastic NK cell lymphoma, agranular CD##+ NK cell leukemia, blastic NK leukemia/ lymphoma, and agranular CD##+ CD##+ hematodermic neoplasm.

  • Cancer
  • Cell Therapy
  • Lymphoma
  • Medical Biotechnology
  • United States

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) - Epidemiology Forecast - 2030

  • $ 3750
  • April 2020
  • 72 pages

In Spain, the findings indicate that the maturational profile of pDC blasts in BPDCN is highly heterogeneous and translates into a wide clinical spectrum-from acute leukemia to mature lymphoma-like behavior, which may also lead to variable diagnosis and treatment.

  • Biopharmaceutical
  • Cancer
  • Cell Therapy
  • Lymphoma
  • Medical Biotechnology

Warm Autoimmune Hemolytic Anemia (WAIHA)- Epidemiology Forecast to 2030

  • $ 3750
  • May 2020
  • 100 pages

‘Warm Autoimmune Hemolytic Anemia (WAIHA)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Warm Autoimmune Hemolytic ...

  • Lymphoma
  • Pathology
  • France
  • Germany
  • United Kingdom

Cytokine Release Syndrome (CRS)-Market Insights, Epidemiology, and Market Forecast–2030

  • $ 6950
  • June 2020
  • 200 pages

lymphoma who are receiving CD##-targeted CAR T-cell therapy.

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • United States

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030

  • $ 6950
  • April 2020
  • 200 pages

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030 ##.

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • United States

Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast—2030

  • $ 4750
  • May 2020
  • 200 pages

Programmed death-ligand ## (PD-L##) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast—2030 ##.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • United States

Small Cell Lung Cancer (SCLC)-Market Insights, Epidemiology and Market Forecast-2030

  • $ 6950
  • May 2020
  • 200 pages

Small Cell Lung Cancer (SCLC)-Market Insights, Epidemiology and Market Forecast-2030 ##.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Therapy
  • United States

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2019

  • $ 1250
  • February 2020
  • 106 pages

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2019 ##.

  • Cancer
  • Lymphoma
  • Pathology


View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on